Pharma Knowledge Management Software Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented, By Deployment (On-Premises, Cloud, and Hybrid), By Organization Size (Small & Medium Enterprises and Large Enterprises), By Region, By Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 5.62 Billion
CAGR (2026-2031)	18.98%
Fastest Growing Segment	Cloud
Largest Market	North America
Market Size (2031)	USD 15.94 Billion

Market Overview

The Global Pharma Knowledge Management Software Market will grow from USD 5.62 Billion in 2025 to USD 15.94 Billion by 2031 at a 18.98% CAGR. Global Pharma Knowledge Management Software consists of specialized digital platforms designed to capture, organize, and retrieve proprietary data across the drug development lifecycle, from discovery to commercialization. These systems are essential for retaining intellectual property, ensuring adherence to stringent regulatory standards, and facilitating seamless collaboration across geodispersed research teams. The market is primarily driven by the critical need to accelerate time-to-market for new therapeutics, the demand for audit-ready compliance documentation, and the imperative to mitigate knowledge loss resulting from workforce turnover or organizational restructuring.

However, the expansion of this market faces a significant challenge in the form of data fragmentation and the prevalence of unstructured legacy information. Integrating disparate data silos into a unified repository remains a complex technical and cultural hurdle for many enterprises. According to the Pistoia Alliance, in 2024, 52% of life science experts identified low-quality and poorly curated datasets as the leading barrier to implementing advanced R&D technologies. This statistic underscores the substantial difficulty pharmaceutical companies encounter in harmonizing their vast information archives into accessible, actionable intelligence.

Key Market Drivers

The rising adoption of cloud-based and AI-driven knowledge solutions is fundamentally reshaping how pharmaceutical enterprises manage their intellectual property. As organizations transition from legacy on-premise silos to integrated digital ecosystems, these advanced technologies are enabling real-time data accessibility and enhanced decision-making capabilities. This shift is critical for handling the massive influx of unstructured data generated by modern R&D, allowing scientists to rapidly retrieve and synthesize information across global teams. According to the Pistoia Alliance, September 2025, 77% of life sciences laboratories expect to utilize artificial intelligence technologies within the next two years, signaling a decisive move towards automated, intelligent knowledge management infrastructures.

Concurrently, the imperative for accelerated drug discovery and reduced time-to-market is forcing companies to optimize their data pipelines to meet aggressive commercial targets. In an environment where patent lifecycles are finite and development costs are exorbitant, knowledge management software becomes the backbone for streamlining workflows and eliminating redundant research. This pressure to innovate faster is exemplified by major industry players setting ambitious output goals; for instance, according to Roche, in 2025, the company outlined a strategic objective to introduce 20 new breakthrough therapies by 2029. To support such high-velocity innovation, significant capital is being directed toward digital and biotech advancements. This trend is evident in the wider market, where, according to Sanofi, October 2025, the company increased its corporate venture capital fund to $1.4 billion to specifically target investments in artificial intelligence and digital health technologies.

Download Free Sample Report

Key Market Challenges

Data fragmentation and the prevalence of unstructured legacy information represent a primary impediment to the expansion of the global pharma knowledge management software market. Pharmaceutical organizations frequently struggle to consolidate proprietary data that is scattered across isolated silos and recorded in inconsistent formats throughout the drug development lifecycle. This disconnection prevents the creation of a unified repository, which is a fundamental requirement for the effective deployment of knowledge management platforms. When critical research data is trapped in disparate systems without a standardized structure, companies face substantial operational delays and increased costs associated with manual data retrieval, directly reducing the efficiency gains that these software solutions are intended to provide.

The persistence of these technical barriers limits the addressable market for knowledge management vendors, as potential clients hesitate to invest in platforms that cannot easily integrate with their existing infrastructure. The inability to harmonize diverse data sources effectively stalls digital transformation initiatives. According to the Pistoia Alliance, in 2024, 60% of life science professionals cited the lack of data interoperability and integration capabilities as a top barrier to adopting data-centric technologies. This statistic highlights a significant market friction, where the resource-intensive nature of structuring legacy data forces enterprises to divert budget and focus away from software acquisition, thereby hampering overall market growth.

Key Market Trends

The Integration of Generative AI for Automated Content Synthesis is fundamentally altering the role of knowledge management systems from passive repositories to active intelligence engines. Pharmaceutical organizations are increasingly deploying these capabilities to automate the creation of complex documentation, such as clinical study reports, safety summaries, and regulatory submissions, thereby reducing manual effort and minimizing human error. This trend addresses the critical bottleneck of regulatory writing by utilizing large language models to extract and synthesize relevant findings from vast historical datasets. According to PharmaTimes, July 2024, in the 'GenAI out of the bottle' report, 53% of regulatory professionals identified a specific need to harness artificial intelligence for information summarization to streamline these labor-intensive documentation processes.

Concurrently, the Adoption of Semantic Search and Enterprise Knowledge Graphs is emerging as a structural necessity to support these advanced AI workflows. To ensure that generative models produce accurate and hallucination-free outputs, companies are transitioning from unstructured data lakes to semantically linked knowledge graphs that enforce data contextualization and traceability. This shift is driven by the requirement to make proprietary data Findable, Accessible, Interoperable, and Reusable (FAIR) across the drug development lifecycle. According to the Pistoia Alliance, September 2024, in the 'Lab of the Future 2024 Global Survey', 38% of life science respondents cited data that does not adhere to FAIR principles as a primary barrier to the effective implementation of AI technologies, underscoring the urgency of this architectural evolution.

Segmental Insights

The cloud deployment segment is currently experiencing the most rapid expansion within the Global Pharma Knowledge Management Software Market. This growth is primarily driven by the increasing demand for remote accessibility and real-time collaboration across geographically dispersed research teams. Pharmaceutical organizations are prioritizing cloud solutions to minimize on-premise infrastructure costs while ensuring scalable data storage that facilitates compliance with stringent data integrity frameworks established by regulatory bodies such as the US Food and Drug Administration. Furthermore, this shift supports the seamless integration of disparate clinical data sources to accelerate drug development cycles.

Regional Insights

North America maintains a leading position in the Global Pharma Knowledge Management Software Market, driven by established healthcare IT infrastructure and a high concentration of major pharmaceutical enterprises. This dominance is fundamentally supported by stringent regulatory requirements from the U.S. Food and Drug Administration (FDA), which mandate rigorous data validation and compliance standards. Consequently, organizations prioritize software implementation to ensure data integrity and streamline complex research and development processes. Additionally, the region’s focus on accelerating drug discovery encourages the adoption of digital platforms that facilitate efficient cross-functional information sharing and intellectual property management.

Recent Developments

• In January 2025, Egnyte announced the issuance of five new patents and the launch of Egnyte Copilot, a generative AI-powered assistant, as part of its continued expansion in the content governance market. The new patents cover innovations in conflict detection for hybrid cloud environments, centralized user access control, and sensitive content analysis, which are critical for regulated industries like pharmaceuticals. The company also released over 300 new product features in the preceding year to improve data security and workflow automation. These developments reflect the growing demand for intelligent software that can manage compliant data lifecycles while leveraging AI for productivity.
• In December 2024, Dotmatics entered into a strategic partnership with Databricks to advance scientific intelligence within the life sciences sector. This collaboration involves deploying the Dotmatics Luma Scientific Intelligence Platform on the Databricks Data Intelligence Platform to unify and analyze massive datasets used in therapeutic discovery. The integration allows researchers to aggregate complex multimodal data, from bench experiments to computational analysis, into intelligent structures that support decision-making. By combining scientific-specific applications with a scalable data lakehouse architecture, the companies aim to resolve challenges related to data fragmentation and accelerate the development of new treatments.
• In September 2024, Veeva Systems announced a major update to Veeva Site Connect, a solution focused on streamlining clinical trial operations between sponsors and research sites. The release introduced capabilities that go beyond simple document exchange to include comprehensive management of study communications, safety distribution, and payment information. These enhancements are designed to create a more connected and efficient ecosystem, reducing the administrative burden associated with site start-up and study execution. The update supports the broader market shift towards unified platforms that ensure data consistency and speed in clinical trials.
• In April 2024, Revvity Signals Software launched Signals Synergy, a new solution designed to facilitate collaboration and data exchange between pharmaceutical sponsors and external contract research organizations. The platform functions as a project management and data stewardship layer, integrating with the company's existing notebook and research suite to replace fragmented communication methods like email. By centralizing data transfer and providing greater visibility into project status, the software aims to minimize errors and delays in the drug development process. This launch addresses the industry's need for secure and efficient scientific data sharing across distributed research networks.

Key Market Players

• SAP SE
• Oracle Corporation
• Dassault Systèmes SE
• ArisGlobal LLC
• MasterControl Inc.
• Accenture plc
• IQVIA Holdings Inc.
• Veeva Systems Inc.
• Honeywell International Inc.
• Sparta Systems Inc.

By Deployment	By Organization Size	By Region
On-Premises Cloud Hybrid	Small & Medium Enterprises and Large Enterprises	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Pharma Knowledge Management Software Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Pharma Knowledge Management Software Market, By Deployment:

• On-Premises
• Cloud
• Hybrid

• Pharma Knowledge Management Software Market, By Organization Size:

• Small & Medium Enterprises and Large Enterprises

• Pharma Knowledge Management Software Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE